Pharos iBio Co., Ltd. (KOSDAQ:388870)
South Korea · Delayed Price · Currency is KRW 5,310.00
+220.00 (4.32%)
At close: Aug 24, 2026
Pharos iBio Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
65.89B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 300.00M | 243.00M | 426.32% |
| Dec 31, 2021 | 57.00M | -130.68M | -69.63% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Daehan Nupharm | 205.39B |
| Jin Yang Pharmaceutical | 124.61B |
| Sinsin Pharmaceutical | 118.65B |
| Hwail Pharmaceutical | 107.87B |
| KOREA PHARMA | 93.94B |
| Sinil Pharmaceutical | 82.18B |
| Sam-A Pharm. | 72.28B |
| Polaris AI Pharma | 63.94B |